MedPacto KRX:235980KOSDAQ
메드팩토 · Korean news coverage and regulatory filings, organized.
Articles, 24h1
Articles, 7 days2
DART filings, 7 days1
Articles tracked2since Sep 11
In Q2 2026, MedPacto reported revenue of ₩1.0bn, up 25.0% year on year, and an operating loss of ₩3.6bn. MedPacto (메드팩토) appeared in 2 Korean news articles and 1 DART filing over the past seven days. Coverage peaked on Sep 13 with 1 article. The most common catalyst was clinical & approvals (1).
MedPacto quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩1.0bn | +25.0% | −₩3.6bn | −₩3.2bn |
| Q1 2026 | ₩1.3bn | +206.2% | −₩4.2bn | −₩3.8bn |
| Q4 2025 derived | ₩1.4bn | – | −₩2.9bn | −₩2.7bn |
| Q3 2025 | ₩1.2bn | – | −₩4.7bn | −₩4.5bn |
| Q2 2025 | ₩840m | – | −₩2.6bn | −₩2.3bn |
| Q1 2025 | ₩430m | – | −₩3.8bn | −₩3.4bn |
| Q4 2024 derived | ₩0m | – | −₩4.8bn | −₩4.4bn |
| Q3 2024 | ₩0m | – | −₩2.2bn | −₩1.8bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases.
MedPacto top stories 2 weeks, by number of outlets
- 1
- 2
